top of page
A pre-operative window study evaluating the biological effects of the RANK-Ligand (RANKL) inhibitor Denosumab on normal breast tissue from BRCA1 or BRCA2 mutation carriers and high-risk non-carriers

Recruiting at: Royal Melbourne Hospital 

Primary Investigator: Professor Geoff Lindeman

Clinical trial register: ACTRN12614000694617

Women aged 18 yrs+ with a confirmed BRCA1 or BRCA2 mutation who are planning to have prophylactic mastectomy OR willing to have two breast biopsies are likely to be eligible for inclusion in this study. A breast biopsy is taken at baseline, and between 1 and 3 doses of denosumab are administered prior to having surgery (or second biopsy). 

For more information, contact​

BRCA-D clinical trial diagram
bottom of page